Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > UPDATED INFO on CXR - GL tomorrow for everyone :)
View:
Post by BaystreetBrian on May 12, 2016 3:38pm

UPDATED INFO on CXR - GL tomorrow for everyone :)

https://research.tdwaterhouse.ca/research/Reports/Report?documentKey=337-CXR.TO_72d147fb85be5fcc1e1c56604b0286ce-5TEOANV9MBU15AMB1AFNU01P06
Comment by visionaryfool on May 12, 2016 3:42pm
Can you put the salient points in this thread?
Comment by wordless on May 12, 2016 3:47pm
I'm not with TD - It wants em to log-in.  Can you post the sumamry on this board?
Comment by BaystreetBrian on May 12, 2016 4:20pm
Providing Insider News and Knowledge to Investors Company Report: Concordia Healthcare Corp. (T:CXR) May 12, 2016 A snap shot of company officer and director insider public-market activity for the past year, recent marker data plus a list of all insider transactions and holdings. Public Market Activity: Company Officers and Directors Price and volume charts represent ...more  
Comment by CCK on May 12, 2016 6:53pm
Brian, can you post the summary from TD?  Don't have access to it.  Thanks.
Comment by Craigbad on May 12, 2016 7:15pm
Here is the justification and risks from td late april cck. Justification of Target Price Our $45.00 target price is based on a 7.5x EV/EBITDA target multiple on our F2017 EBITDA estimate. The valuation multiple reflects the F2017 weighting to "new product" growth'; which introduces development and regulatory risk; and for which there is limited visibility.  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities